Clinical trials
Neuromyelitis Optica trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 25 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Third Affiliated Hospital, Sun Yat-Sen University | 3 |
| Xuanwu Hospital, Beijing | 3 |
| Feng Jinzhou | 2 |
| Tianjin Medical University General Hospital | 2 |
| Beijing Tiantan Hospital | 1 |
| Beijing Tongren Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| Dokuz Eylul University | 1 |
| Hansoh BioMedical R&D Company | 1 |
| Hospices Civils de Lyon | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuromyelitis Optica | 25 |
| Multiple Sclerosis | 9 |
| Autoimmune Diseases of the Nervous System | 2 |
| Encephalomyelitis, Acute Disseminated | 2 |
| Optic Neuritis | 2 |
| Autoimmune Diseases | 1 |
| Cone Dystrophy | 1 |
| Cone-Rod Dystrophies | 1 |
| Demyelinating Diseases | 1 |
| Diffuse Cerebral Sclerosis of Schilder | 1 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.